SCHEMBL9320719

SCHEMBL9320719

COc1cc(O)c(C(=O)O)cc1C12CC3CC(CC(C3)C1)C2

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RARA P10276 6/20 0.52
RARB P10826 6/20 0.52
RARG P13631 6/20 0.52
MEN1 O00255 4/20 0.52
KMT2A Q03164 4/20 0.52
NR1I2 O75469 1/20 0.52
LMNA P02545 1/20 0.52
PGR P06401 1/20 0.52
HSPD1 P10809 1/20 0.52
GOT1 P17174 1/20 0.52
GLRA1 P23415 1/20 0.52
BLM P54132 1/20 0.52
HSPE1 P61604 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
HDAC11 Q96DB2 2/20 0.44
HDAC2 Q92769 1/20 0.44
RORC P51449 1/20 0.43
HDAC1 Q13547 1/20 0.42
HDAC7 Q8WUI4 1/20 0.42
HDAC8 Q9BY41 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9122371 0.89 RARA (0.54) RARARARBRARGMEN1KMT2A
SCHEMBL9320668 0.86 RARA (0.55) RARARARBRARGMEN1KMT2A
SCHEMBL9122383 0.85 KMT2A (0.51) RARARARBRARGMEN1KMT2A
SCHEMBL9160250 0.82 MEN1 (0.52) RARARARBRARGMEN1KMT2A
SCHEMBL9320581 0.82 RARA (0.53) RARARARBRARGMEN1KMT2A
SCHEMBL9292104 0.80 RARA (0.55) RARARARBRARGMEN1KMT2A
SCHEMBL30873722 0.80 KMT2A (0.51) RARARARBRARGMEN1KMT2A
SCHEMBL9125797 0.80 KMT2A (0.51) RARARARBRARGMEN1KMT2A
SCHEMBL29190709 0.80 KMT2A (0.51) RARARARBRARGMEN1KMT2A
SCHEMBL20322856 0.80 PPARG (0.40) RARARARBRARGMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107427431-B Antioxidant or anti-aging composition comprising 5-adamantan-1-yl-N- (2, 4-dihydroxybenzyl) -2, 4-dimethoxybenzamide 株式会社爱茉莉太平洋 2021-04-13 CN disclosed
EP-3278790-B1 ANTI-OXIDATIVE OR ANTI-AGING COMPOSITION CONTAINING 5-ADAMANTAN-1-YL-N-(2,4-DIHYDROXYBENZYL)-2,4-DIMETHOXYBENZAMIDE AMOREPACIFIC CORP (KR) 2021-03-24 EP disclosed
EP-3318550-B1 METHOD FOR PREPARING A BENZOIC ACID AMIDE COMPOUND AMOREPACIFIC CORP (KR) 2020-03-04 EP disclosed
US-20180116933-A1 ANTI-OXIDATIVE OR ANTI-AGING COMPOSITION CONTAINING 5-ADAMANTAN-1-YL-N-(2,4-DIHYDROXYBENZYL)-2,4-DIMETHOXYBENZAMIDE AMOREPACIFIC CORPORATION (KR) 2018-05-03 US disclosed
EP-3278790-A2 ANTI-OXIDATIVE OR ANTI-AGING COMPOSITION CONTAINING 5-ADAMANTAN-1-YL-N-(2,4-DIHYDROXYBENZYL)-2,4-DIMETHOXYBENZAMIDE Amorepacific Corporation (KR) 2018-02-07 EP disclosed
EP-2740721-B1 NOVEL BENZOIC ACID AMIDE COMPOUND AMOREPACIFIC CORP (KR) 2017-03-22 EP disclosed
US-9433593-B1 Composition for anti-inflammation containing 5-adamantan-1-yl-N-(2,4-dihydroxy-benzyl)-2,4-dimethoxy-benzamide AMOREPACIFIC CORPORATION (KR) 2016-09-06 US disclosed
CN-103702977-B Benzoic acid amide compound 株式会社爱茉莉太平洋 2016-08-17 CN disclosed
US-9254251-B2 Benzoic acid amide compound AMOREPACIFIC CORPORATION (KR) 2016-02-09 US disclosed
US-20140234241-A1 NOVEL BENZOIC ACID AMIDE COMPOUND AMOREPACIFIC CORPORATION (KR) 2014-08-21 US disclosed
EP-2740721-A2 NOVEL BENZOIC ACID AMIDE COMPOUND Amorepacific Corporation (KR) 2014-06-11 EP disclosed
CN-103702977-A Novel benzoic acid amide compound AMORE PACIFIC CORP 2014-04-02 CN disclosed
EP-0409729-B1 Bi-aromatic thioesters, process for their preparation and their use in human or veterinary medicine and in cosmetics CIRD GALDERMA (FR) 1994-01-12 EP disclosed
EP-0409729-A1 Bi-aromatic thioesters, process for their preparation and their use in human or veterinary medicine and in cosmetics CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA, ( CIRD GALDERMA) (FR) 1991-01-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140234241-A1 NOVEL BENZOIC ACID AMIDE COMPOUND TYR, AADAC, CUTA RARA 148/4885RARB 216/4885RARG 185/4885
US-20180116933-A1 ANTI-OXIDATIVE OR ANTI-AGING COMPOSITION CONTAINING 5-ADAMANTAN-1-YL-N-(2,4-DIHYDROXYBENZYL)-2,4-DIMETHOXYBENZAMIDE MMP14, DNASE1, MMP15 RARA 2089/4885RARB 1643/4885RARG 2745/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.